Search Results

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that a paper detailing the development of its “off-the-shelf” neoantigen platform, SLATE, recently published in Nature Medicine.

Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid therapy suzetrigine in pain—both slated for January 2025.

The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.

Envoy Medical® Corporation (“Envoy”), a hearing health company, today announced the proposed slate of seven directors to be voted on during the special meeting of stockholders to be held by its merger partner

Apnimed, Inc. announced a series of five data presentations and a dinner symposium at the SLEEP 2024 annual meeting.

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on the highly anticipated MariTide Phase II results slated for late 2024, according to BMO Capital Markets analyst Evan Seigerman.

The Maryland Tech Council, the largest technology and life sciences trade association in the state, welcomed a new chair and slate of technology and life sciences leaders to its board of directors.

Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.

Frontier Medicines Corporation announced the appointment of Gerardo Ubaghs as Chief Financial Officer and the additional close of $20 million extension to its Series C, bringing the total amount raised to $100 million, with the financing slated to accelerate multiple pipeline programs.

Johnson & Johnson’s deal for Numab Therapeutics’ bispecific antibody NM26, slated to enter Phase II studies, comes on the heels of J&J’s $850 million Proteologix bispecific antibody acquisition.